Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Expression of the NF‐κB targets BCL2 and BIRC5/Survivin characterizes small B‐cell and aggressive B‐cell lymphomas, respectively
Lorraine Tracey, Alberto Pérez‐Rosado, María J. Artiga, et al.
The Journal of Pathology (2005) Vol. 206, Iss. 2, pp. 123-134
Closed Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Alain C. Mita, Monica Mita, Steffan T. Nawrocki, et al.
Clinical Cancer Research (2008) Vol. 14, Iss. 16, pp. 5000-5005
Closed Access | Times Cited: 738
Survivin, a cancer target with an emerging role in normal adult tissues
Seiji Fukuda, Louis M. Pelus
Molecular Cancer Therapeutics (2006) Vol. 5, Iss. 5, pp. 1087-1098
Closed Access | Times Cited: 467
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Pérez‐Galán, Martin Dreyling, Adrian Wiestner
Blood (2010) Vol. 117, Iss. 1, pp. 26-38
Open Access | Times Cited: 391
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler, Michael Butterworth, Aneela Majid, et al.
Blood (2008) Vol. 113, Iss. 18, pp. 4403-4413
Open Access | Times Cited: 311
Recent advances in siRNA delivery mediated by lipid-based nanoparticles
Sei Yonezawa, Hiroyuki Koide, Tomohiro Asai
Advanced Drug Delivery Reviews (2020) Vol. 154-155, pp. 64-78
Open Access | Times Cited: 290
The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure
Samantha Kendrick, Hyun-Jin Kang, Mohammad P. Alam, et al.
Journal of the American Chemical Society (2014) Vol. 136, Iss. 11, pp. 4161-4171
Open Access | Times Cited: 248
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Anthony W. Tolcher, Alain C. Mita, Lionel D. Lewis, et al.
Journal of Clinical Oncology (2008) Vol. 26, Iss. 32, pp. 5198-5203
Open Access | Times Cited: 238
The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
Saman Hewamana, Suhair Alghazal, Thet Thet Lin, et al.
Blood (2008) Vol. 111, Iss. 9, pp. 4681-4689
Open Access | Times Cited: 155
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
A. W. Tolcher, David I. Quinn, Anna C. Ferrari, et al.
Annals of Oncology (2011) Vol. 23, Iss. 4, pp. 968-973
Closed Access | Times Cited: 152
Aberrant Lipid Metabolism in Anaplastic Thyroid Carcinoma Reveals Stearoyl CoA Desaturase 1 as a Novel Therapeutic Target
Christina A. Von Roemeling, Laura A. Marlow, Anthony B. Pinkerton, et al.
The Journal of Clinical Endocrinology & Metabolism (2015) Vol. 100, Iss. 5, pp. E697-E709
Open Access | Times Cited: 136
Survivin and YM155: How faithful is the liaison?
Anke Rauch, Dorle Hennig, Claudia Schäfer, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2014) Vol. 1845, Iss. 2, pp. 202-220
Closed Access | Times Cited: 127
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
Laura Tornatore, Annamaria Sandomenico, Domenico Raimondo, et al.
Cancer Cell (2014) Vol. 26, Iss. 4, pp. 495-508
Open Access | Times Cited: 104
Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma
Zakir Khan, Abdul Arif Khan, Hariom Yadav, et al.
Cellular & Molecular Biology Letters (2017) Vol. 22, Iss. 1
Open Access | Times Cited: 102
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, et al.
Blood Advances (2017) Vol. 1, Iss. 14, pp. 933-946
Open Access | Times Cited: 94
BH3-mimetics: recent developments in cancer therapy
Paul A. Townsend, M. V. Kozhevnikova, Olivier Cexus, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 60
Targeting NF-κB in hematologic malignancies
Thomas Braun, G Carvalho, Claire Fabre, et al.
Cell Death and Differentiation (2006) Vol. 13, Iss. 5, pp. 748-758
Open Access | Times Cited: 155
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Abel Sánchez‐Aguilera
Blood (2006) Vol. 108, Iss. 2, pp. 662-668
Open Access | Times Cited: 142
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma
Bruce D. Cheson, Nancy L. Bartlett, Julie M. Vose, et al.
Cancer (2011) Vol. 118, Iss. 12, pp. 3128-3134
Open Access | Times Cited: 107
Intracellular Delivery of a Proapoptotic Peptide via Conjugation to a RAFT Synthesized Endosomolytic Polymer
Craig L. Duvall, Anthony J. Convertine, Danielle S. W. Benoit, et al.
Molecular Pharmaceutics (2009) Vol. 7, Iss. 2, pp. 468-476
Open Access | Times Cited: 99
B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas
Shaoying Li, Adam C. Seegmiller, Pei Lin, et al.
Modern Pathology (2014) Vol. 28, Iss. 2, pp. 208-217
Open Access | Times Cited: 84
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor B pathways
Daniel Medina, Lauri Goodell, John Glod, et al.
Haematologica (2012) Vol. 97, Iss. 8, pp. 1255-1263
Open Access | Times Cited: 84
NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo
Xiaolu Cui, Dezhi Shen, Chuize Kong, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 84
MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Shaoying Li, Pei Lin, Ken H. Young, et al.
Advances in Anatomic Pathology (2013) Vol. 20, Iss. 5, pp. 315-326
Closed Access | Times Cited: 79
Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models
Mohammadjavad Paydar, Behnam Kamalıdehghan, Yi Li Wong, et al.
Drug Design Development and Therapy (2014), pp. 719-719
Open Access | Times Cited: 74
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Y Li, Myriam N. Bouchlaka, Jared Wolff, et al.
Oncogene (2016) Vol. 35, Iss. 48, pp. 6223-6234
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top